A Phase I/II Trial Investigating the Combination of Pembrolizumab (Keytruda) With Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma

Trial Profile

A Phase I/II Trial Investigating the Combination of Pembrolizumab (Keytruda) With Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs Cyclophosphamide (Primary) ; Lenalidomide (Primary) ; Pembrolizumab (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MUKfourteen
  • Most Recent Events

    • 22 Aug 2017 Status changed from not yet recruiting to withdrawn prior to enrolment due to withdrawal of pharma support prior to opening to recruitment
    • 21 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top